A Phase 2 interventional study of Durvalumab in Esophageal Squamous Cell Carcinoma, sponsored by Samsung Medical Center. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-12-17.
Sponsored by Samsung Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Esophageal Squamous Cell Carcinoma with a site in Korea, Republic of — 9 open to participants now, 11 under way, 2 of them phase 3. Esophageal Squamous Cell Carcinoma · Korea, Republic of.
Among the 44 studies in Esophageal Squamous Cell Carcinoma with a site in Korea, Republic of, this one is the 36th largest by planned enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2017, is one of 17 in phase 2, and was the 14th registered.
676 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →9 of the 44 studies in Esophageal Squamous Cell Carcinoma with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Korea, Republic of, United States, Brazil and 9 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Korea, Republic of, United States, Brazil and 13 more countries
Ages 18+
Yuhan Corporation · Sites in Korea, Republic of
Ages 18+
Daiichi Sankyo · Sites in Korea, Republic of, United States, Belgium and 14 more countries
Ages 18+
Alentis Therapeutics AG · Sites in Korea, Republic of, United States, France and 5 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 25 · Phase 3 8
First in 2008; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 64 across 563 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 138 across the 43 interventional studies, 0 across the 1 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 44 have an industry lead sponsor. The 10 most frequent:
Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 9 studies filed under Esophageal Squamous Cell Carcinoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Esophageal Squamous Cell Carcinoma with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04550260Phase 3AstraZenecaStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | 2027-06-30 |
| NCT06975410Yuhan CorporationClinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | 2027-06 |
| NCT05319730Merck Sharp & Dohme LLCA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | 2027-06-11 |
| NCT07405151Merck Sharp & Dohme LLCA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) | 2027-06-12 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add all 7 to your calendar (.ics) → With an account.
Among the 44 studies in Esophageal Squamous Cell Carcinoma with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent radiotherapy for inoperable locally advanced esophageal squamous cell carcinoma. Four weeks after completion of CCRT combined with immunotherapy, 2 cycles of durvaluma and tremelimumab will be administered every 4 weeks and thereafter durvalumab monotherapy Q4W will be maintained until unacceptable toxicity or disease progression, or for maximum 2 years after enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Concurrent radiotherapy with chemotherapy (5FU/CDDP) and immune checkpoint inhibitors (durvalumab/tremelimumab), and followed by consolidation immune checkpoint inhibitors
Drug: Durvalumab
concurrent radiotherapy
Also known as: tremelimumab, 5FU, Cisplatin
This study also gives Tremelimumab. No intervention listed here names it: that was found by reading the record.
Progression-free survival
Time interval from enrollment to disease progression or death
Time frame: 1 year
Started Dec 2017 (actual). Primary completion is estimated for Jun 2021, 42 months after the start.
Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 42 months is close to that.
Counting every sponsor, half of 173 studies reached it within 40 months; a quarter within 28 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tremelimumab
Esophageal Squamous Cell Carcinoma →